Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT03399604
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 121 participants
- Sponsor
- Liquidia Technologies, Inc.
- Registry
-
NCT03399604
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03399604. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2019-05-06 (actual). Results posted on 2024-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
- Acronym
- INSPIRE
- Condition
- Primary Pulmonary Hypertension
- Intervention (Drug)
- LIQ861 Inhaled Treprostinil
- Lead sponsor
- Liquidia Technologies, Inc.
- Collaborator
- Nuventra, Inc.
Record details
- Record id
cardio:ct-nct03399604- Content hash
5ddb34b90e7a0179ceeeba08d9944a001071f00eac31ffd70c60fc39480c1c30